Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (H-share ticker: 02196) announced that its controlling subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd. ("Yaoyou Pharma"), has obtained conditional approval from the National Medical Products Administration (NMPA) for the GR1803 injection.

On May 28, 2026, Yaoyou Pharma entered into a licensing agreement with Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. ("Zhixiang Jintai"), securing exclusive rights for the clinical development and commercialization of the licensed product, a bispecific antibody targeting both BCMA and CD3 with GR1803 as its sole active ingredient, across mainland China, Hong Kong, Macau, and Taiwan. The agreement also grants Yaoyou Pharma exclusive rights to process research and production, with Yaoyou Pharma designated as the Marketing Authorization Holder (MAH) for the product within the licensed territory.

Recently, the GR1803 injection (generic name: Weilitumimab injection; trade name in mainland China: Weiketo®) received conditional approval from the NMPA for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. GR1803 is a bispecific antibody that simultaneously binds to BCMA and CD3 antigens, thereby redirecting cytotoxic T cells to BCMA-expressing cells.

Beyond the newly approved indication, as of the announcement date (August 27, 2026), multiple clinical studies are underway in mainland China evaluating the drug for adult relapsed or refractory multiple myeloma, systemic lupus erythematosus, and other conditions. According to the latest IQVIA MIDAS data, global sales of BCMA×CD3-targeting antibody drugs reached approximately USD 1.139 billion in 2025. To date, two BCMA×CD3-targeting antibody products have received conditional market approval in mainland China: Pfizer Inc.'s elranatamab injection (approved in March 2025) and Janssen-Cilag International NV's teclistamab injection (approved in June 2024).

The approval of this drug offers a new therapeutic option for adult patients with relapsed or refractory multiple myeloma in mainland China and further enriches the product pipeline of the Group, which encompasses the Company and its controlling subsidiaries. Going forward, Yaoyou Pharma and Zhixiang Jintai will proceed with the transfer of the Marketing Authorization Holder (MAH) designation in accordance with the agreement.